BTIG's Rating and Price Target#
BTIG has reiterated a Buy rating for GE HealthCare (NASDAQ:GEHC) and set a price target of $85.00. This target suggests potential growth from the current stock price of $74.15. According to analysis, the stock is considered undervalued, with a Fair Value estimated at $88.69, making it one of the more attractive options in the healthcare equipment sector.
Analyzing Revenue and Orders Growth#
The firm conducted an analysis of GE HealthCare's orders and revenue growth from Q1 2022 to Q4 2025. They examined how organic revenue growth correlates with various indicators, including orders, the book-to-bill ratio (which compares the amount of new orders to the amount of revenue), remaining performance obligations, and backlog. The strongest correlation was found between organic revenue growth and backlog growth, with a predictive power of about 0.914, indicating a strong relationship. Interestingly, orders growth showed a weaker correlation than expected.
Insights on Backlog Conversion#
The analysis suggests that orders typically convert into revenue within a six-month timeframe once they enter the backlog. However, BTIG noted that the results are based on a limited dataset for 2024-2025. They also mentioned that factors such as site readiness and pricing dynamics complicate straightforward forecasting.
Recent Developments at GE HealthCare#
In addition to the rating, GE HealthCare has been active in various initiatives. The company is leading the COMPASS consortium, a five-year project under the EU’s Innovative Health Initiative, focused on early detection of cardiovascular risks in cancer patients, involving over 60 partners and a budget of €50.5 million. Furthermore, GE HealthCare is expanding its collaboration with DeepHealth, Inc. to enhance AI-driven mammography tools and has integrated its bkActiv ultrasound system with Medtronic’s surgical navigation system for improved real-time visualization during surgeries. Additionally, Stifel has also maintained a Buy rating for GE HealthCare with a price target of $98.00, following discussions about its advanced CT technology. Lastly, GE HealthCare cautioned investors about an unsolicited offer from Potemkin Limited to buy shares at a significantly lower price than the market value.